ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

ClinicalTrials.gov ID: NCT01532089

Public ClinicalTrials.gov record NCT01532089. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 12:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase II Trial of Erlotinib Alone or in Combination With Bevacizumab in Patients With Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

Study identification

NCT ID
NCT01532089
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Academic and Community Cancer Research United
Other
Enrollment
88 participants

Conditions and interventions

Interventions

  • Bevacizumab Biological
  • Erlotinib Drug
  • Erlotinib Hydrochloride Drug
  • Laboratory Biomarker Analysis Other

Biological · Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 15, 2012
Primary completion
Feb 12, 2018
Completion
Aug 17, 2020
Last update posted
Oct 5, 2020

2012 – 2020

United States locations

U.S. sites
19
U.S. states
13
U.S. cities
19
Facility City State ZIP Site status
UC San Diego Moores Cancer Center La Jolla California 92093
Heartland Cancer Research NCORP Decatur Illinois 62526
Illinois CancerCare-Peoria Peoria Illinois 61615
Carle Cancer Center NCI Community Oncology Research Program Urbana Illinois 61801
Michigan Cancer Research Consortium NCORP Ann Arbor Michigan 48106
Cancer Research Consortium of West Michigan NCORP Grand Rapids Michigan 49503
Mayo Clinic Rochester Minnesota 55905
Coborn Cancer Center at Saint Cloud Hospital Saint Cloud Minnesota 56303
Washington University School of Medicine St Louis Missouri 63110
New Hampshire Oncology Hematology PA-Hooksett Hooksett New Hampshire 03106
Hematology Oncology Associates of Central New York-East Syracuse East Syracuse New York 13057
State University of New York Upstate Medical University Syracuse New York 13210
UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27599
Duke University Medical Center Durham North Carolina 27710
Sanford Broadway Medical Center Fargo North Dakota 58122
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
Upstate Carolina CCOP Spartanburg South Carolina 29303
Rapid City Regional Hospital Rapid City South Dakota 57701
Saint Vincent Hospital Cancer Center Green Bay Green Bay Wisconsin 54301

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01532089, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 5, 2020 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01532089 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →